Cargando…
Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure
AIMS: The arginine vasopressin (AVP) pathway has been extensively studied in heart failure (HF) with reduced ejection fraction (HFrEF), but less is known about AVP in HF with preserved EF (HFpEF). Furthermore, the association between AVP and atrial natriuretic peptide (ANP, a well‐known inhibitor of...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165935/ https://www.ncbi.nlm.nih.gov/pubmed/29969536 http://dx.doi.org/10.1002/ehf2.12319 |
_version_ | 1783359936922648576 |
---|---|
author | Chirinos, Julio A. Sardana, Mayank Oldland, Garrett Ansari, Bilal Lee, Jonathan Hussain, Anila Mustafa, Anique Akers, Scott R. Wei, Wen Lakatta, Edward G. Fedorova, Olga V. |
author_facet | Chirinos, Julio A. Sardana, Mayank Oldland, Garrett Ansari, Bilal Lee, Jonathan Hussain, Anila Mustafa, Anique Akers, Scott R. Wei, Wen Lakatta, Edward G. Fedorova, Olga V. |
author_sort | Chirinos, Julio A. |
collection | PubMed |
description | AIMS: The arginine vasopressin (AVP) pathway has been extensively studied in heart failure (HF) with reduced ejection fraction (HFrEF), but less is known about AVP in HF with preserved EF (HFpEF). Furthermore, the association between AVP and atrial natriuretic peptide (ANP, a well‐known inhibitor of AVP secretion) in HF is unknown. METHODS AND RESULTS: We studied subjects with HFpEF (n = 28) and HFrEF (n = 25) and without HF (n = 71). Left ventricular (LV) mass and left atrial (LA) volumes were measured with cardiac magnetic resonance imaging. Arginine vasopressin and ANP were measured with enzyme‐linked immunosorbent assay. Arginine vasopressin levels were significantly greater in HFpEF [0.96 pg/mL; 95% confidence interval (CI) = 0.83–1.1 pg/mL] compared with subjects without HF (0.69 pg/mL; 95% CI = 0.6–0.77 pg/mL; P = 0.0002). Heart failure with preserved ejection fraction (but not HFrEF) was a significant predictor of higher AVP after adjustment for potential confounders. Arginine vasopressin levels were independently associated with a greater LA volume and also paradoxically, with lower ANP levels. Key independent correlates of higher AVP were the presence of HFpEF (standardized β = 0.32; 95% CI = 0.09–0.56; P = 0.0073) and the ANP/LA volume ratio (standardized β = −0.23; 95% CI = −0.42 to −0.04; P = 0.0196). Arginine vasopressin levels were independently associated with LV mass (β = 0.26; 95% CI = 0.09–0.43; P = 0.003) and with an increased risk of death or HF admissions during follow‐up (hazard ratio = 1.61; 95% CI = 1.13–2.29; P = 0.008). CONCLUSIONS: Arginine vasopressin is increased in HFpEF and is associated with LV hypertrophy and poor outcomes. Higher AVP is associated with the combination of LA enlargement and paradoxically low ANP levels. These findings may indicate that a relative deficiency of ANP (an inhibitor of AVP secretion) in the setting of chronically increased LA pressure may contribute to AVP excess. |
format | Online Article Text |
id | pubmed-6165935 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61659352018-10-04 Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure Chirinos, Julio A. Sardana, Mayank Oldland, Garrett Ansari, Bilal Lee, Jonathan Hussain, Anila Mustafa, Anique Akers, Scott R. Wei, Wen Lakatta, Edward G. Fedorova, Olga V. ESC Heart Fail Original Research Articles AIMS: The arginine vasopressin (AVP) pathway has been extensively studied in heart failure (HF) with reduced ejection fraction (HFrEF), but less is known about AVP in HF with preserved EF (HFpEF). Furthermore, the association between AVP and atrial natriuretic peptide (ANP, a well‐known inhibitor of AVP secretion) in HF is unknown. METHODS AND RESULTS: We studied subjects with HFpEF (n = 28) and HFrEF (n = 25) and without HF (n = 71). Left ventricular (LV) mass and left atrial (LA) volumes were measured with cardiac magnetic resonance imaging. Arginine vasopressin and ANP were measured with enzyme‐linked immunosorbent assay. Arginine vasopressin levels were significantly greater in HFpEF [0.96 pg/mL; 95% confidence interval (CI) = 0.83–1.1 pg/mL] compared with subjects without HF (0.69 pg/mL; 95% CI = 0.6–0.77 pg/mL; P = 0.0002). Heart failure with preserved ejection fraction (but not HFrEF) was a significant predictor of higher AVP after adjustment for potential confounders. Arginine vasopressin levels were independently associated with a greater LA volume and also paradoxically, with lower ANP levels. Key independent correlates of higher AVP were the presence of HFpEF (standardized β = 0.32; 95% CI = 0.09–0.56; P = 0.0073) and the ANP/LA volume ratio (standardized β = −0.23; 95% CI = −0.42 to −0.04; P = 0.0196). Arginine vasopressin levels were independently associated with LV mass (β = 0.26; 95% CI = 0.09–0.43; P = 0.003) and with an increased risk of death or HF admissions during follow‐up (hazard ratio = 1.61; 95% CI = 1.13–2.29; P = 0.008). CONCLUSIONS: Arginine vasopressin is increased in HFpEF and is associated with LV hypertrophy and poor outcomes. Higher AVP is associated with the combination of LA enlargement and paradoxically low ANP levels. These findings may indicate that a relative deficiency of ANP (an inhibitor of AVP secretion) in the setting of chronically increased LA pressure may contribute to AVP excess. John Wiley and Sons Inc. 2018-07-03 /pmc/articles/PMC6165935/ /pubmed/29969536 http://dx.doi.org/10.1002/ehf2.12319 Text en Published 2018. This article is a U.S. Government work and is in the public domain in the USA. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Articles Chirinos, Julio A. Sardana, Mayank Oldland, Garrett Ansari, Bilal Lee, Jonathan Hussain, Anila Mustafa, Anique Akers, Scott R. Wei, Wen Lakatta, Edward G. Fedorova, Olga V. Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure |
title | Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure |
title_full | Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure |
title_fullStr | Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure |
title_full_unstemmed | Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure |
title_short | Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure |
title_sort | association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165935/ https://www.ncbi.nlm.nih.gov/pubmed/29969536 http://dx.doi.org/10.1002/ehf2.12319 |
work_keys_str_mv | AT chirinosjulioa associationofargininevasopressinwithlowatrialnatriureticpeptidelevelsleftventricularremodellingandoutcomesinadultswithandwithoutheartfailure AT sardanamayank associationofargininevasopressinwithlowatrialnatriureticpeptidelevelsleftventricularremodellingandoutcomesinadultswithandwithoutheartfailure AT oldlandgarrett associationofargininevasopressinwithlowatrialnatriureticpeptidelevelsleftventricularremodellingandoutcomesinadultswithandwithoutheartfailure AT ansaribilal associationofargininevasopressinwithlowatrialnatriureticpeptidelevelsleftventricularremodellingandoutcomesinadultswithandwithoutheartfailure AT leejonathan associationofargininevasopressinwithlowatrialnatriureticpeptidelevelsleftventricularremodellingandoutcomesinadultswithandwithoutheartfailure AT hussainanila associationofargininevasopressinwithlowatrialnatriureticpeptidelevelsleftventricularremodellingandoutcomesinadultswithandwithoutheartfailure AT mustafaanique associationofargininevasopressinwithlowatrialnatriureticpeptidelevelsleftventricularremodellingandoutcomesinadultswithandwithoutheartfailure AT akersscottr associationofargininevasopressinwithlowatrialnatriureticpeptidelevelsleftventricularremodellingandoutcomesinadultswithandwithoutheartfailure AT weiwen associationofargininevasopressinwithlowatrialnatriureticpeptidelevelsleftventricularremodellingandoutcomesinadultswithandwithoutheartfailure AT lakattaedwardg associationofargininevasopressinwithlowatrialnatriureticpeptidelevelsleftventricularremodellingandoutcomesinadultswithandwithoutheartfailure AT fedorovaolgav associationofargininevasopressinwithlowatrialnatriureticpeptidelevelsleftventricularremodellingandoutcomesinadultswithandwithoutheartfailure |